BRPI0810641A2 - "compostos farmacêuticos". - Google Patents

"compostos farmacêuticos".

Info

Publication number
BRPI0810641A2
BRPI0810641A2 BRPI0810641A BRPI0810641A BRPI0810641A2 BR PI0810641 A2 BRPI0810641 A2 BR PI0810641A2 BR PI0810641 A BRPI0810641 A BR PI0810641A BR PI0810641 A BRPI0810641 A BR PI0810641A BR PI0810641 A2 BRPI0810641 A2 BR PI0810641A2
Authority
BR
Brazil
Prior art keywords
disorders
pharmaceutical compounds
function
compounds
pi3k
Prior art date
Application number
BRPI0810641A
Other languages
English (en)
Inventor
Mcdonald Edward
Amandine Dechaux Elsa
Martin Large Jonathan
Anthony Pegg Neil
John Goldsmith Paul
Joseph Shuttleworth Stephen
Price Stephen
Colin Hancox Timothy
Original Assignee
Hoffmann La Roche
The Institute Of Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707088A external-priority patent/GB0707088D0/en
Priority claimed from GB0707611A external-priority patent/GB0707611D0/en
Application filed by Hoffmann La Roche, The Institute Of Cancer Res filed Critical Hoffmann La Roche
Publication of BRPI0810641A2 publication Critical patent/BRPI0810641A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)
BRPI0810641A 2007-04-12 2008-04-14 "compostos farmacêuticos". BRPI0810641A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707088A GB0707088D0 (en) 2007-04-12 2007-04-12 Pharmaceutical compounds
GB0707611A GB0707611D0 (en) 2007-04-19 2007-04-19 Pharmaceutical compounds
PCT/GB2008/001301 WO2008125839A2 (en) 2007-04-12 2008-04-14 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase

Publications (1)

Publication Number Publication Date
BRPI0810641A2 true BRPI0810641A2 (pt) 2019-09-24

Family

ID=39832798

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810641A BRPI0810641A2 (pt) 2007-04-12 2008-04-14 "compostos farmacêuticos".

Country Status (13)

Country Link
US (1) US20100130496A1 (pt)
EP (1) EP2150546B1 (pt)
JP (1) JP2010523639A (pt)
KR (1) KR20100016433A (pt)
CN (1) CN101765597A (pt)
AT (1) ATE496045T1 (pt)
AU (1) AU2008237721A1 (pt)
BR (1) BRPI0810641A2 (pt)
CA (1) CA2683624A1 (pt)
DE (1) DE602008004650D1 (pt)
IL (1) IL201365A0 (pt)
MX (1) MX2009010886A (pt)
WO (1) WO2008125839A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810646A2 (pt) * 2007-04-12 2014-11-04 Hoffmann La Roche " compostos farmacêuticos ".
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
CA2733533C (en) 2008-08-25 2013-12-17 Irm Llc Hedgehog pathway modulators
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010092962A1 (ja) 2009-02-12 2010-08-19 アステラス製薬株式会社 へテロ環誘導体
CN102711766B (zh) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
CN102712642B (zh) 2009-11-12 2015-08-12 霍夫曼-拉罗奇有限公司 N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2604601B1 (en) 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
US8877934B2 (en) 2010-09-29 2014-11-04 Intervet Inc. N-heteroaryl compounds
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6117235B2 (ja) 2011-12-15 2017-04-19 ノバルティス アーゲー Ｐｉ３ｋの活性または機能の阻害剤の使用
WO2013144179A1 (en) 2012-03-28 2013-10-03 Intervet International B.V. Heteroaryl compounds with a-cyclic bridging unit
EP2852661A1 (en) 2012-05-23 2015-04-01 F. Hoffmann-La Roche AG Compositions and methods of obtaining and using endoderm and hepatocyte cells
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2015071230A1 (en) * 2013-11-15 2015-05-21 Bayer Cropscience Ag Catalytic hydrogenation of nitriles
CA2940237C (en) 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
DK3558944T3 (da) 2016-12-21 2022-05-30 Bayer Cropscience Ag Hydrogenering af et substitueret 2-methylcyanopyridylderivat i nærvær af en raney-cobaltkatalysator
AU2018269947B2 (en) * 2017-05-15 2021-10-14 The Regents Of The University Of Michigan Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
EP4069366B1 (en) 2019-12-04 2025-03-19 CHDI Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
CN115515588A (zh) 2020-02-14 2022-12-23 萨克生物研究学院 大环ulk1/2抑制剂
AU2021218739A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Inhibitors of ULK1/2 and methods of using same
CN119841806A (zh) * 2023-10-16 2025-04-18 中国医学科学院药物研究所 多取代的喹唑啉类化合物及其制备方法、用途和药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
ATE527250T1 (de) * 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
CA2527079A1 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
EP1745033A4 (en) * 2004-05-08 2009-08-26 Neurogen Corp 2-ARYLPYRIMIDINES DISUBSTITUTED IN 4,5
WO2006060194A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2008237721A1 (en) 2008-10-23
DE602008004650D1 (de) 2011-03-03
CN101765597A (zh) 2010-06-30
EP2150546A2 (en) 2010-02-10
WO2008125839A2 (en) 2008-10-23
MX2009010886A (es) 2009-12-14
ATE496045T1 (de) 2011-02-15
IL201365A0 (en) 2010-05-31
CA2683624A1 (en) 2008-10-23
KR20100016433A (ko) 2010-02-12
US20100130496A1 (en) 2010-05-27
WO2008125839A3 (en) 2008-12-24
JP2010523639A (ja) 2010-07-15
EP2150546B1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
IL201365A0 (en) Pyrimidine derivatives as inhibitors of phosphatidylinositol - 3 kinase
MX2009010881A (es) Compuestos farmaceuticos.
GB0423653D0 (en) Pharmaceutical compounds
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2009053715A8 (en) Thienopyrimidiene derivatives as pi3k inhibitors
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2006067445A3 (en) Csf-1r kinase inhibitors
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
IL198116A (en) Carboxamides of pyrimidine that are annealed to rings of 5 and 6 atoms including nitrogen atom and their pharmacy preparations
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
UA115320C2 (uk) Інгібітори кінази
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
WO2007113558A8 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
EA201101507A1 (ru) Способы лечения солидных опухолей
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.